AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15126514 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 490
Study 11453891 — intervention group
Group type: EXPERIMENTAL
Intervention: Flomoxef (1 g) at 09.00 h
Number of subjects: 8
Study 11453891 — intervention group
Group type: EXPERIMENTAL
Intervention: Flomoxef (1 g) at 21.00 h
Number of subjects: 8
Study 9556895 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotics
Number of subjects: 80
Study 9556895 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Control)
Number of subjects: 80
Study 8301766 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 194
Study 8301766 — intervention group
Group type: COMPARATOR
Intervention: Friendly Visits (FVs)
Number of subjects: 194
Study 2647666 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 20 mg i.v.
Number of subjects: 60
Study 2647666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29868715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (notified prescribers)
Number of subjects: 877
Study 29868715 — intervention group
Group type: COMPARATOR
Intervention: Control group (not notified prescribers)
Number of subjects: 877
Study 29868715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 877
Study 29018067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives administering 600 µg misoprostol orally
Number of subjects: 1094
Study 29018067 — intervention group
Group type: COMPARATOR
Intervention: Physicians administering 600 µg misoprostol orally
Number of subjects: 1094
Study 29018067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives and physicians providing contraceptive counselling
Number of subjects: 1094
Study 29018067 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives and physicians administering misoprostol
Number of subjects: 1094
Study 25453392 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring care (TELE)
Number of subjects: 205
Study 25453392 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 205
Study 23873553 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymol + carvacrol at 200 mg/kg diet
Number of subjects: 60
Study 23873553 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymol + carvacrol
Number of subjects: 60
Study 23873553 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 60
Study 22161921 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-head metal-on-metal bearing
Number of subjects: 100
Study 22161921 — intervention group
Group type: COMPARATOR
Intervention: 28 mm diameter conventional metal-on-polyethylene bearing
Number of subjects: 100
Study 19630538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbicide with protection properties
Number of subjects: 408
Study 19630538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbicide could prevent BV
Number of subjects: 408
Study 19630538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbicide could prevent vaginal odor
Number of subjects: 408
Study 19630538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal microbicide could prevent vaginal itching and burning
Number of subjects: 408
Study 19630538 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of vaginal microbicide
Number of subjects: 408
Study 16687907 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression decompression CPR
Number of subjects: 0
Study 16687907 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory impedance threshold valve
Number of subjects: 0
Study 16687907 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased chest and abdominal compression‐decompression CPR
Number of subjects: 0
Study 16687907 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of diastolic blood pressure
Number of subjects: 0
Study 16687907 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of myocardial perfusion pressure
Number of subjects: 0
Study 16687907 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of end‐tidal CO2
Number of subjects: 0
Study 16687907 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Number of subjects: 0
Study 15753151 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (2000 IU/day, 2 years)
Number of subjects: 0
Study 15753151 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (400 IU/day, 1 month) + Vitamin C (1000 g/day)
Number of subjects: 0
Study 15753151 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 0
Study 11408497 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR detection of PSA mRNA
Number of subjects: 193
Study 11408497 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR for PSA
Number of subjects: 193
Study 9064059 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tabs/day)
Number of subjects: 1473
Study 7761669 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening i.v. administration of erythropoietin (rHuEPO)
Number of subjects: 26
Study 7761669 — intervention group
Group type: COMPARATOR
Intervention: Morning i.v. administration of erythropoietin (rHuEPO)
Number of subjects: 26
Study 3554459 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis
Number of subjects: 206
Study 29970071 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal home visits to pregnant women and their partners
Number of subjects: 1800
Study 29970071 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal home visits with added video edutainment
Number of subjects: 1800
Study 29970071 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 1800
Study 27545119 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR252067 (40, 120, 300, 600, 900, or 1200 mg)
Number of subjects: 48
Study 27545119 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR252067 (40 mg)
Number of subjects: 48
Study 27545119 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR252067
Number of subjects: 48
Study 27545119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25691681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide 1.0-3.0 g/day (4.0 ± 1.5 tablets/day)
Number of subjects: 644
Study 25691681 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer 2.4-14.4 g/day (10.1 ± 6.6 tablets/day)
Number of subjects: 644
Study 23543427 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test (TET) for elderly patients with CHD
Number of subjects: 110
Study 21569380 — intervention group
Group type: COMPARATOR
Intervention: Normal Control (NC)
Number of subjects: 59
Study 21569380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 59
Study 21569380 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease (AD)
Number of subjects: 59
Study 18460643 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (escalating doses)
Number of subjects: 25
Study 17974096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate
Number of subjects: 0
Study 14507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W1 (65% VO2max, 300 kcal in one daily walking bout)
Number of subjects: 255
Study 14507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W2 (65% VO2max, 300 kcal in two daily walking bouts)
Number of subjects: 255
Study 14507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W1 and W2 combined
Number of subjects: 255
Study 14507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W3 (55% VO2max, 300 kcal)
Number of subjects: 255
Study 14507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W4 (45% VO2max, 300 kcal)
Number of subjects: 255
Study 14507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W5 (55% VO2max, 200 kcal)
Number of subjects: 255
Study 14507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group W6 (45% VO2max, 200 kcal)
Number of subjects: 255
Study 11115683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant use
Number of subjects: 20
Study 9210002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 215
Study 8425281 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring (HM) combined with exercise testing
Number of subjects: 486
Study 8425281 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiological study (EPS)
Number of subjects: 486
Study 8425281 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring (HM)
Number of subjects: 486
Study 3303936 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (11 patients)
Number of subjects: 20
Study 3303936 — intervention group
Group type: COMPARATOR
Intervention: Control (9 patients)
Number of subjects: 20
Study 31618698 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestive therapies
Number of subjects: 332
Study 31618698 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobese HFpEF)
Number of subjects: 332
Study 29550099 — intervention group
Group type: EXPERIMENTAL
Intervention: Battlefield acupuncture (BFA) plus standard care
Number of subjects: 30
Study 29550099 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 30
Study 29138200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 200
Study 29138200 — intervention group
Group type: COMPARATOR
Intervention: Control group (offspring of women without GDM)
Number of subjects: 200
Study 29138200 — intervention group
Group type: EXPERIMENTAL
Intervention: Foetal echography
Number of subjects: 200
Study 29138200 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography (2-7 days after birth)
Number of subjects: 200
Study 29138200 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness measurement
Number of subjects: 200
Study 26501831 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic magnesium infusion (initial loading dose 30 mg/kg over 15 minutes followed by continuous infusion 10 mg/kg/h)
Number of subjects: 60
Study 26501831 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 60
Study 26501831 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic magnesium infusion
Number of subjects: 60
Study 24171961 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved PAD (subcutaneous injection of bortezomib)
Number of subjects: 36
Study 24171961 — intervention group
Group type: COMPARATOR
Intervention: PAD (conventional treatment)
Number of subjects: 36
Study 24171961 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved PAD
Number of subjects: 36
Study 24171961 — intervention group
Group type: COMPARATOR
Intervention: PAD
Number of subjects: 36
Study 20508979 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (IT)
Number of subjects: 40
Study 20508979 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 40
Study 18309943 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodality therapy (cisplatin 100 mg/m² and fluorouracil 1,000 mg/m²/d for 4 days on weeks 1 and 5 concurrent with radiation therapy 50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection
Number of subjects: 56
Study 18309943 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 56
Study 16845626 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted APSV (1:5 and 1:10)
Number of subjects: 91
Study 16845626 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted APSV
Number of subjects: 91
Study 12702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 30‐45 mg/day
Number of subjects: 197
Study 12702891 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20‐30 mg/day
Number of subjects: 197
Study 12848626 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (15-25 mg)
Number of subjects: 10
Study 12848626 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate with 5 mg folic acid (15-25 mg)
Number of subjects: 10
Study 12848626 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous methotrexate (15-25 mg)
Number of subjects: 10
Study 10589962 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (MMF, CsA, and prednisone)
Number of subjects: 52
Study 10589962 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of CsA (group B)
Number of subjects: 52
Study 10589962 — intervention group
Group type: COMPARATOR
Intervention: Continuation of triple therapy (group A)
Number of subjects: 52
Study 10589962 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of prednisone (group C)
Number of subjects: 52
Study 8704533 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 38
Study 8704533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 1872925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil dietary supplementation (10 g/day)
Number of subjects: 8
Study 6343861 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (1500 mg/m²/day for one week)
Number of subjects: 94
Study 6343861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 3709648 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72.222, 20 mg (slow i.v. injection)
Number of subjects: 6
Study 3709648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31482354 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLaST‐SS©
Number of subjects: 14
Study 31482354 — intervention group
Group type: COMPARATOR
Intervention: FLS
Number of subjects: 14
Study 29898677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led case management intervention with targeted recommendations
Number of subjects: 127
Study 29133336 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 522
Study 29133336 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 522
Study 29133336 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 522
Study 25445871 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring visible to staff
Number of subjects: 154
Study 25445871 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring without capnography visibility (Control)
Number of subjects: 154
Study 24259108 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX‐ON setting (variable beam diameter)
Number of subjects: 12
Study 24259108 — intervention group
Group type: COMPARATOR
Intervention: MAX‐OFF setting (4-mm-diameter spot)
Number of subjects: 12
Study 21554269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia
Number of subjects: 1749
Study 21554269 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sodium
Number of subjects: 1749
Study 18373843 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM+X (gemcitabine-based combination chemotherapy)
Number of subjects: 4465
Study 18373843 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based combinations (GEM+platinum)
Number of subjects: 4465
Study 18373843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine-based combinations (GEM+fluoropyrimidine)
Number of subjects: 4465
Study 18373843 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM+irinotecan, exatecan or pemetrexed
Number of subjects: 4465
Study 18373843 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM+X in patients with good performance status (PS)
Number of subjects: 4465
Study 18373843 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM+X in patients with poor performance status (PS)
Number of subjects: 4465
Study 16931265 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior capsule polishing
Number of subjects: 65
Study 16931265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anterior capsule polishing)
Number of subjects: 65
Study 12608675 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 20
Study 12608675 — intervention group
Group type: COMPARATOR
Intervention: Conventional second-stage surgery
Number of subjects: 20
Study 11279553 — intervention group
Group type: EXPERIMENTAL
Intervention: IDUs and crack cocaine smokers
Number of subjects: 216
Study 11279553 — intervention group
Group type: COMPARATOR
Intervention: White men who have sex with both White and Alaska Native women
Number of subjects: 216
Study 9091027 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-16 mg, mean final dose 6.1 mg)
Number of subjects: 61
Study 9091027 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (10-20 mg, mean final dose 15.6 mg)
Number of subjects: 61
Study 8365297 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (2 g IV over 20 min followed by 2 g/h over 4 h)
Number of subjects: 48
Study 8365297 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate bolus (2 g over 20 min followed by placebo infusion)
Number of subjects: 48
Study 8365297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (loading dose and infusion)
Number of subjects: 48
Study 3632987 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dramatics with videotape feedback
Number of subjects: 15
Study 3632987 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 29082602 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermotherapy (one session)
Number of subjects: 52
Study 29082602 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (every 2 to 3 weeks up to six sessions if required)
Number of subjects: 52
Study 27301489 — intervention group
Group type: EXPERIMENTAL
Intervention: Organisational change intervention including smoke-free policy development, staff training, educational resources, and free nicotine replacement therapy.
Number of subjects: 33
Study 27301489 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control services.
Number of subjects: 33
Study 25187104 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose with 2.4 g · kg(‐1) · day(‐1) amino acids
Number of subjects: 132
Study 25187104 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 132
Study 23842110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624
Number of subjects: 118
Study 23842110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 21169169 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psycho-education program
Number of subjects: 370
Study 21169169 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of noncompleters
Number of subjects: 370
Study 21169169 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 370
Study 18246696 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg 4 times daily for adults; 20 to 40 mg/kg daily in 4 divided doses for children
Number of subjects: 184
Study 18246696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (an emollient cream)
Number of subjects: 184
Study 16540709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia training (IHT) in hypoxia (FiO2 = 14.5%); 6 weeks duration; included two weekly high-intensity training sessions.
Number of subjects: 18
Study 16540709 — intervention group
Group type: COMPARATOR
Intervention: Normoxia training (Nor group; FiO2 = 20.9%); 6 weeks duration; included two weekly high-intensity training sessions.
Number of subjects: 18
Study 12733136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening (invitation to screening every 18 months)
Number of subjects: 51611
Study 11533797 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 78
Study 11533797 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 9412256 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g.kg-1 HBOC-201
Number of subjects: 12
Study 9412256 — intervention group
Group type: COMPARATOR
Intervention: 3 ml.kg-1 6% HES 70,000/0.5
Number of subjects: 12
Study 8241226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine target trough level reduced from 400-600 micrograms/L to 200-400 micrograms/L (Group A)
Number of subjects: 28
Study 8241226 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine target trough level maintained at 400-600 micrograms/L (Group B)
Number of subjects: 28
Study 8241226 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 28
Study 3888708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% domoprednate
Number of subjects: 17
Study 3888708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% domoprednate
Number of subjects: 17
Study 3888708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% hydrocortisone butyrate
Number of subjects: 17
Study 3888708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate
Number of subjects: 17
Study 3888708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasole propionate
Number of subjects: 17
Study 3888708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31119486 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical navigation (SN)
Number of subjects: 53
Study 31119486 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical navigation (non-SN)
Number of subjects: 53
Study 28116514 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression CT (n=71)
Number of subjects: 168
Study 28116514 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol CT (n=97)
Number of subjects: 168
Study 28116514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 168
Study 28116514 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression CT
Number of subjects: 168
Study 25981560 — intervention group
Group type: EXPERIMENTAL
Intervention: -318 C/T genotype in acute rejection group
Number of subjects: 34
Study 25981560 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele at -318 position
Number of subjects: 34
Study 22537207 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (q.d.) pramipexole
Number of subjects: 590
Study 22537207 — intervention group
Group type: COMPARATOR
Intervention: Three-times-daily (t.i.d.) pramipexole
Number of subjects: 590